Cencora (COR) AI Stock Analysis

• Market Cap: $68.63B
• Dividend Yield: 0.62%
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): 44.5
• Beta (1Y): 0.08
• Revenue Growth: 9.31%
• EPS Growth: 5.92%
• Country: US
• Employees: 42,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 3.84
• Shares Outstanding: 193,877,880
• 10 Day Avg. Volume: 1,555,473
• 30 Day Avg. Volume: 1,298,008
• PEG Ratio: 6.89
• Price to Book (P/B): 34.69
• Price to Sales (P/S): 0.19
• P/FCF Ratio: 18.90
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 0.20
• Enterprise Value/Gross Profit: 6.59
• Enterprise Value/Ebitda: 15.93
• 1Y Price Target: $374.44
• Price Target Upside: 3.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: $400.00 ▲(10.90% Upside)

Cencora's overall stock score of 76 reflects strong financial performance and positive earnings call sentiment, driven by strategic investments and robust growth in specialty markets. However, high leverage and valuation concerns, along with potential short-term technical pullbacks, temper the outlook.

Positive Factors

Revenue Growth

Projected revenue growth of 5%-7% for FY26 indicates a strong market position and continued demand for Cencora's services, supporting long-term expansion.

Strategic Investments

Significant investment in infrastructure enhances Cencora's distribution capabilities, ensuring long-term competitive advantage and operational efficiency.

Cash Flow Generation

Strong cash flow generation provides financial flexibility for strategic investments and debt management, supporting sustainable growth.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, impacting Cencora's ability to invest in growth opportunities and weather economic downturns.

PharmaLex Challenges

Ongoing challenges in the PharmaLex business could hinder overall profitability and require strategic realignment, affecting long-term performance.

Net Interest Expense Increase

Rising interest expenses due to increased debt levels can strain cash flow, reducing funds available for growth initiatives and impacting financial health.

Cencora Business Overview & Revenue Model

Company Description

Cencora (COR) is a global leader in the pharmaceutical supply chain, specializing in providing comprehensive services for the healthcare and life sciences sectors. The company operates in various segments, including logistics, distribution, and regulatory compliance, offering a suite of products and services designed to ensure the efficient delivery of pharmaceuticals and medical devices. Cencora focuses on enhancing supply chain performance for pharmaceutical manufacturers, healthcare providers, and patients through innovative solutions and robust infrastructure.

How the Company Makes Money

Cencora generates revenue through multiple key streams, primarily by offering logistics and distribution services to pharmaceutical companies. The company charges fees for warehousing, inventory management, and transportation of pharmaceutical products. Additionally, Cencora earns revenue by providing regulatory compliance consulting services, assisting clients in navigating the complex landscape of drug approval and safety regulations. Significant partnerships with major pharmaceutical manufacturers and healthcare institutions also bolster its earnings, as these collaborations often lead to long-term contracts and recurring revenue. Furthermore, Cencora may benefit from value-added services, such as temperature-controlled shipping and real-time tracking solutions, which command premium pricing.

Cencora Financial Statement Overview

Summary

Cencora demonstrates solid revenue growth and cash flow generation, but faces challenges with high leverage and relatively low margins. The company needs to focus on improving operational efficiency and managing its debt levels to enhance financial stability.

Income Statement

Cencora has shown consistent revenue growth over the years, with a slight dip in net profit margin in the latest year. The gross profit margin has improved slightly, indicating better cost management. However, the EBIT and EBITDA margins are relatively low, suggesting room for improvement in operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio, which poses a risk in terms of financial leverage. However, the return on equity has improved significantly, indicating better utilization of equity. The equity ratio is low, suggesting a heavy reliance on debt financing.

Cash Flow

Cencora's cash flow position is strong, with significant growth in free cash flow. The operating cash flow to net income ratio indicates efficient cash generation relative to net income. The free cash flow to net income ratio is robust, showing good cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	316.65B	321.33B	293.96B	262.17B	238.59B	213.99B
Gross Profit	9.70B	10.49B	8.70B	7.76B	7.60B	6.27B
EBITDA	4.01B	3.70B	3.36B	3.41B	3.11B	2.91B
Net Income	1.90B	1.55B	1.51B	1.75B	1.70B	1.54B
Balance Sheet
Total Assets	73.96B	76.59B	67.10B	62.56B	56.56B	57.34B
Cash, Cash Equivalents and Short-Term Investments	2.23B	4.36B	3.13B	2.59B	3.39B	2.55B
Total Debt	8.24B	7.66B	4.39B	4.79B	5.70B	6.68B
Total Liabilities	71.75B	74.84B	66.31B	61.89B	56.49B	56.75B
Stockholders Equity	1.98B	1.75B	645.94M	522.00M	-211.56M	223.35M
Cash Flow
Free Cash Flow	1.14B	3.21B	3.00B	3.45B	2.21B	2.23B
Operating Cash Flow	1.74B	3.88B	3.48B	3.91B	2.70B	2.67B
Investing Cash Flow	-4.90B	-4.98B	-618.10M	-2.60B	-368.44M	-6.14B
Financing Cash Flow	1.98B	2.25B	-2.33B	-2.22B	-1.75B	1.95B

Cencora Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 360.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COR, the sentiment is Positive. The current price of 360.7 is above the 20-day moving average (MA) of 334.56, above the 50-day MA of 314.27, and above the 200-day MA of 287.44, indicating a bullish trend. The MACD of 11.90 indicates Negative momentum. The RSI at 81.14 is Negative, neither overbought nor oversold. The STOCH value of 87.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COR.

Cencora Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COR	76 Outperform	$68.63B	44.47	129.89%	0.62%	9.31%	5.92%
MCK	72 Outperform	$105.01B	26.29	―	0.36%	17.23%	66.17%
PDCO	70 Outperform	―	―	―	―	-0.85%	-23.40%
HSIC	69 Neutral	$8.48B	22.14	11.39%	―	3.51%	29.65%
CAH	65 Neutral	$46.76B	29.71	―	1.04%	4.37%	28.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	38 Underperform	$259.11M	―	-184.47%	―	-37.09%	-2639.44%

Cencora Corporate Events

Cencora, Inc. Reports Strong Fiscal 2025 Results

Cencora, Inc. is a leading global pharmaceutical solutions organization that partners with pharmaceutical innovators to improve market access to therapies, focusing on secure and reliable delivery of pharmaceuticals and healthcare products. In its fiscal year 2025, Cencora reported a revenue increase of 9.3% to $321.3 billion, with a 5.7% rise in GAAP diluted EPS to $7.96 and a 16.3% increase in adjusted diluted EPS to $16.00. The company also announced a 9% increase in its quarterly dividend and raised its long-term guidance expectations.

Cencora, Inc. Reports Strong Fiscal 2025 Earnings

Cencora, Inc. recently held its earnings call for fiscal 2025, revealing a robust financial performance that has set a positive tone among investors and stakeholders. The company reported significant growth in operating income and earnings per share (EPS), alongside strategic investments aimed at bolstering future growth. Despite challenges in its PharmaLex business, the overall sentiment remains optimistic due to Cencora’s strong market positioning and financial results.

Cencora Reports Strong Q4 Revenue Growth and Dividend Increase

On November 5, 2025, Cencora reported its fiscal 2025 fourth quarter and year-end results, highlighting a 5.9% increase in fourth-quarter revenue to $83.7 billion and a 9.3% rise in annual revenue to $321.3 billion. Despite a GAAP diluted EPS loss of $1.75 in the fourth quarter, the adjusted EPS increased to $3.84. The company also raised its quarterly dividend by 9% and its long-term guidance, reflecting confidence in continued growth driven by strategic acquisitions and a focus on digital transformation. These results underscore Cencora’s strengthened position in the healthcare market and its commitment to driving stakeholder value.

The most recent analyst rating on (COR) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Cencora Amends Credit Agreements for Enhanced Flexibility

On September 5, 2025, Cencora, Inc. amended its Term Credit Agreement, originally dated November 26, 2024, to adjust the maturity date to October 1, 2027, and modify the interest rate structure based on public debt ratings. Additionally, Cencora amended its Money Market Facility Agreement to allow borrowings up to $750 million during certain periods, enhancing its financial flexibility. These amendments are likely to impact Cencora’s operational strategies and financial positioning, offering greater adaptability in managing its credit facilities.

The most recent analyst rating on (COR) stock is a Hold with a $306.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Cencora Settles Stockholder Derivative Action for $111.3M

On September 3, 2025, Cencora announced a court-approved agreement to resolve a stockholder derivative action filed by the Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan. The complaint, initiated on December 30, 2021, alleged breaches of fiduciary duty related to the oversight of Cencora’s controlled substance diversion control programs. The settlement, reached after a successful mediation, involves insurance carriers paying Cencora $111.3 million, excluding legal fees, without any admission of liability from the defendants. This resolution marks a significant step in addressing claims against the company’s management and could impact its financial standing and stakeholder relations.

The most recent analyst rating on (COR) stock is a Hold with a $306.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Cencora Appoints New Chairman Effective October 2025

On August 27, 2025, Cencora announced the appointment of D. Mark Durcan as the new Chairman of the Board, effective October 1, 2025. Durcan, who has been a director since 2015 and Lead Independent Director since March 2023, will succeed Steven H. Collis, who will retire at the end of the fiscal year. This leadership transition is expected to support Cencora’s continued growth and leadership in the healthcare industry, leveraging Durcan’s extensive experience in strategic planning and technological innovation.

The most recent analyst rating on (COR) stock is a Hold with a $300.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Cencora, Inc. Reports Strong Q3 2025 Financial Results

Cencora, Inc. is a leading global pharmaceutical solutions organization that partners with pharmaceutical innovators to optimize market access to therapies, serving both human and animal health sectors. The company recently reported robust financial results for its fiscal 2025 third quarter, with revenue reaching $80.7 billion, marking an 8.7% increase year-over-year. The company also saw a significant rise in its GAAP diluted earnings per share (EPS) to $3.52, up from $2.42 in the prior year, and adjusted diluted EPS increased to $4.00 from $3.34.

Cencora’s Earnings Call: Strong Growth Amid Challenges

Cencora, Inc. recently held its earnings call, revealing a generally positive sentiment with strong financial results. The company demonstrated significant growth in operating income and earnings per share (EPS), particularly within the U.S. Healthcare Solutions segment. Despite some challenges in the International Healthcare Solutions segment and moderated growth in GLP-1 sales, the raised fiscal 2025 guidance and leadership in the specialty market suggest a favorable outlook.

Cencora Reports Strong Q3 2025 Financial Results

On August 6, 2025, Cencora announced its fiscal third-quarter results for 2025, reporting an 8.7% increase in revenue to $80.7 billion compared to the previous year. The company’s GAAP diluted EPS rose to $3.52, while adjusted diluted EPS increased to $4.00, leading to an upward revision of its fiscal 2025 EPS guidance. The growth was attributed to strategic acquisitions and a focus on digital transformation, talent investment, and productivity, enhancing its position as a preferred partner in the healthcare sector.

The most recent analyst rating on (COR) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.